Dapagliflozin in ATTR Cardiac Amyloidosis (QoL and Exercise Capacity)

Phase 2, randomised trial in amyloidotic transthyretin cardiomyopathy (ATTR-CM) and heart failure (HF) comparing Dapagliflozin + standard of care with Standard of care alone (2 arms). Primary endpoint: Absolute change in 6-minute walking distance. Planned start Jun 2023; status: authorised.